Literature DB >> 20727050

Inverse expression of estrogen receptor-beta and nuclear factor-kappaB in urinary bladder carcinogenesis.

Stylianos Kontos1, Athina Kominea, Maria Melachrinou, Eleni Balampani, Georgia Sotiropoulou-Bonikou.   

Abstract

OBJECTIVES: To investigate the expression of nuclear factor-kappaB (NF-kappaB) and estrogen receptor-beta (ER-beta) signalling pathways in bladder urothelial carcinoma according to clinicopathological features, in order to elucidate their role during carcinogenesis.
METHODS: Immunohistochemical methodology was carried out on formalin-fixed, paraffin-embedded sections from urinary bladder carcinomas of 140 patients (94 males and 46 females) who underwent transurethral resection of bladder neoplasms. Correlations between ER-beta and NF-kappaB, and tumor grade and T-stage were evaluated, along with demographic data, sex and age.
RESULTS: A significant decrease in ER-beta expression in the nucleus of bladder cells during loss of cell differentiation (r(s) = -0.61, P-value < 0.001, test of trend P-value = 0.003) and in muscle invasive carcinomas (T2-T4; test of trend P-value < 0.001) was found. p65 Subunit of NF-kappaB was expressed in the nucleus and in the cytoplasm of bladder epithelial cells. A strong positive association between tumor grade and nuclear expression of NF-kappaB was shown. No correlation between NF-kappaB, nuclear or cytoplasmic staining, with T-stage was observed. An inverse correlation between ER-beta and nuclear p65 immunoreactivity was observed (r(s) = -0.45, P-value < 0.001). There was no correlation with demographic data.
CONCLUSIONS: Our immunohistochemical study suggests the possible inverse regulation of NF-kappaB and ER-beta transcription factor during bladder carcinogenesis. Selective ER-beta agonists and agents, inhibitors of NF-kappaB, might represent a possible new treatment strategy for bladder urothelial tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20727050     DOI: 10.1111/j.1442-2042.2010.02603.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  23 in total

1.  Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract.

Authors:  Eiji Kashiwagi; Kazutoshi Fujita; Seiji Yamaguchi; Hiroaki Fushimi; Hiroki Ide; Satoshi Inoue; Taichi Mizushima; Leonardo O Reis; Rajni Sharma; George J Netto; Norio Nonomura; Hiroshi Miyamoto
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

2.  High NF-κB and STAT3 activity in human urothelial carcinoma: a pilot study.

Authors:  Marina Degoricija; Marijan Situm; Jelena Korać; Ana Miljković; Katarina Matić; Martina Paradžik; Ivana Marinović Terzić; Ana Jerončić; Snježana Tomić; Janoš Terzić
Journal:  World J Urol       Date:  2014-01-22       Impact factor: 4.226

3.  Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.

Authors:  Bangmin Han; Di Cui; Yifeng Jing; Yan Hong; Shujie Xia
Journal:  World J Urol       Date:  2014-02       Impact factor: 4.226

Review 4.  To be an ally or an adversary in bladder cancer: the NF-κB story has not unfolded.

Authors:  Neelam Mukherjee; Tiffani J Houston; Eduardo Cardenas; Rita Ghosh
Journal:  Carcinogenesis       Date:  2014-12-27       Impact factor: 4.944

Review 5.  Role of oestrogen receptors in bladder cancer development.

Authors:  Iawen Hsu; Spencer Vitkus; Jun Da; Shuyuan Yeh
Journal:  Nat Rev Urol       Date:  2013-04-16       Impact factor: 14.432

6.  Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.

Authors:  Kristi L Hoffman; Seth P Lerner; Carolyn L Smith
Journal:  Horm Cancer       Date:  2012-09-11       Impact factor: 3.869

7.  Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen.

Authors:  Suraj Konnath George; Veronica Tovar-Sepulveda; Steven S Shen; Weiguo Jian; Yiqun Zhang; Susan G Hilsenbeck; Seth P Lerner; Carolyn L Smith
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

8.  Chronic inflammation in urothelial bladder cancer.

Authors:  Gabriella Nesi; Stefania Nobili; Tommaso Cai; Saverio Caini; Raffaella Santi
Journal:  Virchows Arch       Date:  2015-08-12       Impact factor: 4.064

9.  Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.

Authors:  Bangmin Han; Di Cui; Yifeng Jing; Yan Hong; Shujie Xia
Journal:  World J Urol       Date:  2012-01-12       Impact factor: 4.226

Review 10.  Sex Hormone Receptor Signaling in Bladder Cancer: A Potential Target for Enhancing the Efficacy of Conventional Non-Surgical Therapy.

Authors:  Hiroki Ide; Hiroshi Miyamoto
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.